 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
With Cancer Drug Nearing End of Phase Ib/IIa Trial, Senesco Exploring Partnership Opportunities
February 28, 2013
With Cancer Drug Nearing End of Phase Ib/IIa Trial, Senesco Exploring Partnership Opportunities
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Plant Biotech Firm Venganza Secures US Patent on RNAi Technology
June 20, 2013 / Gene Silencing News - Monsanto Forms Honey Bee Advisory Council
June 20, 2013 / Gene Silencing News - Silence Cancer Drug Advances into Phase IIa Portion of Clinical Study
June 20, 2013 / Gene Silencing News - Tools & Techniques: Quantum Dot-based microRNA Detection; siRNA Delivery to Leukemia Cells; and More
June 20, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Asuragen, Merck, Alnylam, and More
June 20, 2013 / Gene Silencing News